u/employer_carveout

and check the full plan document, not the summary. mine had a carve-out that appeared nowhere in the benefits summary HR sent me.

Are you comparing against phase 3 numbers for something else? They are not comparable.

Why mechanism talk keeps misleading people, including me.

A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.

The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.

the glucagon component is why the metabolic story reads differently

Why mechanism talk keeps misleading people, including me.

A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.

The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

Kept a log specifically because there is so little published. It is one person and it is not data.

The GIP question, which is the most interesting unsettled thing in this field.

Dual agonism at GIP and GLP-1 receptors produces clinical results that are robust and well replicated. What is not settled is the mechanism by which the GIP arm contributes — there is a genuine scientific argument about agonism versus antagonism at that receptor, with reasonable people and real data on both sides.

It is worth sitting with that. The clinical effect is not in doubt; the explanation is. That is an ordinary state of affairs in pharmacology and it is a good corrective to the confident mechanistic stories that circulate here.

the peripheral and central stories are not in competition

On the thin testing history in this board, and what to do about it.

Most of the compounds discussed here have a handful of independent results across the entire site, and several have none. That is a fact about how few members have paid for testing, not a judgement about the material.

What follows: buy small, test identity first for anything unusual, and post the result even when it is unremarkable. The vendor source pages are built from exactly these submissions, and the compounds with the thinnest coverage are the ones where one more entry changes the picture most. Research material is not approved for human use, so what this board can usefully build is an analytical record.

Not convinced by the attribution. Weight loss alone moves that marker and you have no way to separate the two.

heart rate is the thing people report watching

Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.

dose escalation in the trials was slow for a reason

Read the phase 2 hepatic paper properly and the endpoint definitions were more interesting than the headline response rate.

research material is not approved for human use, which is why the clinical record here is thin

That figure is from the obesity programme, and this thread is about the hepatic one.

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

That method was developed for a different compound class and would not resolve the impurities you are asking about.

Has anyone posted an independent test on this compound recently?

the sequence is the product, everything else is packaging

Was completely wrong about the gastric emptying story in a thread here two years ago.

Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.

The endpoint vocabulary, because you cannot read this literature without it.

Resolution of steatohepatitis without worsening of fibrosis and improvement in fibrosis without worsening of steatohepatitis are the two standard composite endpoints, both scored on biopsy by pathologists against a defined system. Liver fat fraction is an imaging surrogate that correlates imperfectly with histology.

A trial can move the surrogate substantially and the histological endpoint modestly. Both results are real; they answer different questions. Anybody quoting a response rate here should say which endpoint it refers to, and most summaries do not.

That comparison crosses two labs with different assays. The difference you are describing may be the method.

Careful — that is a claim about efficacy and there is essentially no human evidence behind it.

Time of day, fasting state, hydration and recent exercise all move common markers. Standardising the draw conditions is free and it removes most of the apparent variability.

Tried to build a mental model from mechanism alone and produced a confident prediction that the trial data flatly contradicted.

the phase 2 numbers were striking and they were also 48 weeks in a small population

a mechanism you can state is not a mechanism you have demonstrated

I would not draw a line through two points, especially when the second was taken at a different time of day.

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

phase 2 in liver disease is a different evidence question from weight

Are you reading the publication or a summary?

Why mechanism talk keeps misleading people, including me.

A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.

The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.

hydration status moves a surprising number of markers

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.

Yes. Naming conventions in this corner are loose enough that the same word covers several different molecules.

the energy-expenditure story is mechanistically interesting and clinically unproven

Agreed that thin testing here says something about the members, not about the material.